Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
beLP1-D is a postbiotic formulation developed by the South Korean company Bereum, consisting of heat-killed *Lactobacillus plantarum* (strain beLP1) mixed with maltodextrin. As a postbiotic, it utilizes tyndallized (heat-treated) non-viable microbial cells and their structural components to confer health benefits to the host. The 'D' designation refers to a standardized mixed powder formulation containing 10% active postbiotic material and 90% maltodextrin as a carrier. The mechanism of action involves the interaction of bacterial cell wall components, such as peptidoglycans and lipoteichoic acids, with host immune receptors (e.g., Toll-like receptors) to modulate immune responses and support intestinal barrier function. It is primarily marketed as a functional raw material for use in dietary supplements, functional foods, and dermaceuticals to promote immune health and microbiome balance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on beLP1-D.